Gotham Asset Management LLC Buys 36,742 Shares of The Clorox Company (NYSE:CLX)

Gotham Asset Management LLC increased its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 145.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 62,064 shares of the company's stock after buying an additional 36,742 shares during the quarter. Gotham Asset Management LLC owned about 0.05% of Clorox worth $10,080,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Integral Investment Advisors Inc. grew its position in Clorox by 4.1% during the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after acquiring an additional 67 shares during the last quarter. HCR Wealth Advisors increased its position in Clorox by 1.0% in the fourth quarter. HCR Wealth Advisors now owns 6,870 shares of the company's stock worth $1,116,000 after purchasing an additional 68 shares during the period. Sound View Wealth Advisors Group LLC raised its stake in shares of Clorox by 6.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after buying an additional 77 shares during the last quarter. Wedbush Securities Inc. lifted its stake in shares of Clorox by 1.2% in the 4th quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock valued at $1,238,000 after purchasing an additional 94 shares during the period. Finally, Brooklyn Investment Group boosted its holdings in Clorox by 163.8% during the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock worth $25,000 after buying an additional 95 shares during the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Stock Up 1.2%

Shares of CLX traded up $1.58 on Thursday, reaching $134.99. The company's stock had a trading volume of 1,566,890 shares, compared to its average volume of 1,313,760. The Clorox Company has a twelve month low of $127.60 and a twelve month high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The firm has a fifty day moving average of $141.56 and a 200-day moving average of $153.64. The stock has a market capitalization of $16.64 billion, a PE ratio of 36.88, a PEG ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter last year, the business posted $1.71 earnings per share. Clorox's revenue was down 8.0% on a year-over-year basis. Equities analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were given a dividend of $1.22 per share. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.62%. Clorox's dividend payout ratio is presently 87.61%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CLX. JPMorgan Chase & Co. dropped their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. DA Davidson lowered their price target on Clorox from $171.00 to $169.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. UBS Group lowered their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Morgan Stanley decreased their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, Citigroup reduced their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $151.23.

Insider Activity

In other news, Director Pierre R. Breber acquired 4,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director now owns 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.57% of the company's stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.